187 related articles for article (PubMed ID: 35176142)
1. A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.
Omer B; Cardenas MG; Pfeiffer T; Daum R; Huynh M; Sharma S; Nouraee N; Xie C; Tat C; Perconti S; Van Pelt S; Scherer L; DeRenzo C; Shum T; Gottschalk S; Arber C; Rooney CM
Cancer Immunol Res; 2022 Apr; 10(4):512-524. PubMed ID: 35176142
[TBL] [Abstract][Full Text] [Related]
2. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
[TBL] [Abstract][Full Text] [Related]
3. Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells.
Sharma S; Sauer T; Omer BA; Shum T; Rollins LA; Rooney CM
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958791
[TBL] [Abstract][Full Text] [Related]
4. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
5. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
6. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.
Sharma S; Woods M; Mehta NU; Sauer T; Parikh KS; Schmuck-Henneresse M; Zhang H; Mehta B; Brenner MK; Heslop HE; Rooney CM
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072346
[TBL] [Abstract][Full Text] [Related]
7. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
[TBL] [Abstract][Full Text] [Related]
8. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of chimeric antigen receptor of humanized rabbit-derived T cell receptor-like antibody.
Nakamura T; Kobayashi E; Hamana H; Hayakawa Y; Muraguchi A; Hayashi A; Ozawa T; Kishi H
Cancer Sci; 2022 Oct; 113(10):3321-3329. PubMed ID: 35766417
[TBL] [Abstract][Full Text] [Related]
10. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
11. TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer.
Karahan ZS; Aras M; Sütlü T
Turk J Haematol; 2023 Feb; 40(1):1-10. PubMed ID: 36719099
[TBL] [Abstract][Full Text] [Related]
12. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
13. Cellular Immunotherapy in Lymphoma: Beyond CART Cells.
Gaballa MR; Ramos CA
Curr Treat Options Oncol; 2020 Feb; 21(3):21. PubMed ID: 32048071
[TBL] [Abstract][Full Text] [Related]
14. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
15. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN
Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
[TBL] [Abstract][Full Text] [Related]
17. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
Sharma P; Kranz DM
Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
[TBL] [Abstract][Full Text] [Related]
18. Rapid Generation of TCR and CD8αβ Transgenic Virus Specific T Cells for Immunotherapy of Leukemia.
Bajwa G; Arber C
Front Immunol; 2022; 13():830021. PubMed ID: 35572604
[TBL] [Abstract][Full Text] [Related]
19. Identification of Functional HLA-A*01:01-Restricted Epstein-Barr Latent Membrane Protein 2-Specific T-Cell Receptors.
Huisman W; Gille I; van der Maarel LE; Hageman L; Morton LT; de Jong RCM; Heemskerk MHM; Amsen D; Falkenburg JHF; Jedema I
J Infect Dis; 2022 Sep; 226(5):833-842. PubMed ID: 32808978
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
